Halozyme Therapeutics, Inc. (NASDAQ: HALO) continues to pick itself in the market despite the U.S Food and Drug Administration ordering it to stop the study of its drug, PEGPH20, used in the treatment of pancreatic cancer. The company had stopped the study voluntarily before the FDA made the announcement. Halozyme Therapeutics, Inc. (NASDAQ:HALO) shares after opening at $7.75 moved to $7.75 on last trade day and at the end of the day closed at $7.39. Company price to sales ratio in past twelve months was calculated as 16.79 and price to cash ratio as 12.87. Halozyme Therapeutics, Inc. (NASDAQ:HALO) showed a negative weekly performance of -10.86%.
Shareholder rights law firm Robbins Arroyo LLP announces that an investor of Imperva, Inc. (NYSE:IMPV) has filed a federal securities fraud class action complaint in the U.S District Court for the Northern District of California. Imperva Inc. (NYSE:IMPV) shares advanced 0.53% in last trading session and ended the day on $26.56. IMPV return on equity ratio is recorded as -29.80% and its return on assets is -15.80%. Imperva Inc. (NYSE:IMPV) yearly performance is -32.79%.
Spherix Inc. (NASDAQ:SPEX) on 31 march announced a corporate update disclosing the 101 patents and patent applications acquired in December from Rockstar Consortium. Spherix Inc. (NASDAQ:SPEX) shares moved down -12.20% in last trading session and was closed at $1.80, while trading in range of $1.74 – $2.11. Spherix Inc. (NASDAQ:SPEX) year to date (YTD) performance is -77.67%.
Transition Therapeutics (NASDAQ:TTHI) had its price target upped by Canaccord Genuity from C$9.80 to C$13.25 in a research note issued to investors on Tuesday, Analyst Ratings Network.com reports. Transition Therapeutics Inc. (USA) (NASDAQ:TTHI) weekly performance is -36.93%. On last trading day company shares ended up $4.97. Transition Therapeutics Inc. (USA) (NASDAQ:TTHI) distance from 50-day simple moving average (SMA50) is -31.22%. Analysts mean target price for the company is $12.38.